BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 25696863)

  • 1. All transplantation-eligible patients with myeloma should receive ASCT in first response.
    Moreau P; Attal M
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):250-4. PubMed ID: 25696863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?
    Richardson PG; Laubach JP; Munshi NC; Anderson KC
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):255-61. PubMed ID: 25696864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
    Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving role of stem cell transplantation in multiple myeloma.
    Harousseau JL; Moreau P
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):89-95. PubMed ID: 16231846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma.
    Offidani M; Leoni P; Corvatta L; Polloni C; Gentili S; Savini A; Alesiani F; Brunori M; Catarini M; Visani G; Samori A; Burattini M; Centurioni R; Montanari M; Fraticelli P; Ruggieri M; Falcioni S; Galieni P
    Eur J Haematol; 2010 Jun; 84(6):474-83. PubMed ID: 20331733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment for patients with newly diagnosed multiple myeloma in 2015.
    Mateos MV; Ocio EM; Paiva B; Rosiñol L; Martínez-López J; Bladé J; Lahuerta JJ; García-Sanz R; San Miguel JF
    Blood Rev; 2015 Nov; 29(6):387-403. PubMed ID: 26094881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stem Cell Transplantation in Multiple Myeloma.
    Offidani M; Gentili S; Gay F; Aghemo E; Maracci L; Corvatta L; Palumbo A
    Curr Cancer Drug Targets; 2017; 17(9):769-781. PubMed ID: 27659429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
    Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction.
    Gao W; Geng C; Zhang L; Li Y; Chen W; Wang C
    Hematology; 2013 Nov; 18(6):341-7. PubMed ID: 23510553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to select among available options for the treatment of multiple myeloma.
    Harousseau JL
    Ann Oncol; 2012 Sep; 23 Suppl 10():x334-8. PubMed ID: 22987987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of consolidation therapy in transplant eligible multiple myeloma patients.
    Cavo M; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Zamagni E
    Semin Oncol; 2013 Oct; 40(5):610-7. PubMed ID: 24135406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
    Roussel M; Facon T; Moreau P; Harousseau JL; Attal M
    Recent Results Cancer Res; 2011; 183():189-206. PubMed ID: 21509686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction therapy in multiple myeloma.
    Harousseau JL
    Hematology Am Soc Hematol Educ Program; 2008; ():306-12. PubMed ID: 19074101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem-cell transplantation for multiple myeloma in the era of novel drugs.
    Bensinger W
    J Clin Oncol; 2008 Jan; 26(3):480-92. PubMed ID: 18056678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
    Quach H; Joshua D; Ho J; Szer J; Spencer A; Harrison SJ; Mollee P; Roberts AW; Horvath N; Talaulikar D; To B; Zannettino A; Brown R; Catley L; Augustson B; Jaksic W; Gibson J; Prince HM
    Intern Med J; 2015 Jan; 45(1):94-105. PubMed ID: 25582938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
    Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
    Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontline therapy of multiple myeloma.
    Moreau P; Attal M; Facon T
    Blood; 2015 May; 125(20):3076-84. PubMed ID: 25838345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.